Elk Velvet Antler For Pain Associated With RA

[Guest guest]

Elk Equities Inc: Pilot Study Validates The Merit ofElk Velvet Antler on

Pain Associated With Rheumatoid Arthritis

Press Release: Monday December 11, 10:27 am Eastern Time

CALGARY, ALBERTA--Results of velvet antler study open the Door for Phase

III Clinical Trial. Elk Equities Inc. (CDNX: EVA), together with its

wholly owned subsidiary Qeva Velvet Products Corp., announced the

results of a pilot study conducted by Dr. n from the

University of Alberta.

The month long pilot study found an observed 25% decrease of pain

associated with Rheumatoid Arthritis in the study group taking elk

velvet antler (EVA) compared to a decrease in pain of 5% in the control

group who were not given EVA.

These results open the door for a Phase III Clinical Trial. The

triple-blind, placebo-controlled, randomized clinical trial is being

conducted over a 6-month period using a total of 220 patients. Outcome

criteria and methods of assessment will be the well-validated core set

outlined by the American College of Rheumatology. These include: patient

assessment of pain; tender joint count; swollen joint count; patient

global assessment of disease activity; physician global assessment of

disease activity; acute phase reactant protein; and assessment of

functional ability and quality of life. This research will also be

conducted by Dr. n from the University of Alberta.

``This is exciting news,'' said Pek, President of Elk Equities

Inc. ``This pilot study continues to build the scientific case for the

effectiveness of Elk Velvet Antler. Velvet Antler has been used for

centuries as a natural tonic, primarily in the Asian culture and Qeva is

focused on adding scientific credibility to the thousands of years of

anecdotal evidence and moving into Phase III Clinical Trials will add to

that scientific base of knowledge. This also compliments studies being

done in the animal sector and the positive results being reported for

many pets.''

``The positive results of our pilot study provide us with the indication

we needed to proceed to Phase III Clinical Trials,'' stated Dr. n

, PhD, University of Alberta. ``We found a 25% decrease in pain

associated with Rheumatoid Arthritis in the group taking EVA, compared

to the 5% decrease the control group reported. This difference is

statistically significant and may indicate a positive effect by EVA on

pain associated with Rheumatoid Arthritis.''

About Elk Equities Inc.

Elk Equities Inc. (CDNX: EVA) is a company focused on the research and

product development of such natural remedies as elk velvet antler. The

Natural products market is a $14 billion industry and growing at double

digits annually. Elk Equities Inc. includes three wholly owned

subsidiaries, Qeva Velvet Products Corp., E & R Elk Consulting Ltd., and

The Canadian Elk and Deer Farmer Ltd.

Qeva Velvet Products Corp. is a biotech marketing and research company

focused on the sale of natural medicinal products such as velvet antler.

Natural products are an increasing trend for consumers looking for

alternative health care that is safe and effective. Qeva is successfully

marketing velvet antler for both humans and arthritic pets, under the

name ``Qeva Elk Velvet Antler'' in over 350 health food and pet food

stores across North America, including Canadian Superstore, Shoppers

Drug Mart, Super Drug Mart, Pet Land and Pet Planet. Qeva sponsored

research includes double blind placebo controlled studies that will help

to validate the benefits of velvet antler.

E & R Elk Consulting Ltd. is a consulting and marketing company that

operates on the genetics side of the elk industry. E & R manages live

elk auctions and markets semen from superior genetic elk bloodlines. E &

R will manage $1.5 - $2 million worth of transactions over the last

quarter of 2000.

The Canadian Elk & Deer Farmer Ltd. Publishes the Canadian Elk & Deer

Farmer Magazine, which is the National Advertising and Communication

source for the Elk industry. Revenues are generated from advertising

sales.

Contact:

Qeva Velvet Products Corp.

Pek President and CEO

1-877-355-8324 Website: www.qeva.com